Midas Pharma GmbH

July 18, 2023 – Munich (Germany) – leon-nanodrugs GmbH (“LEON”), the leading enabler of nano technology for the pharmaceutical industry, announced today the appointment of Dr. Hans Frickel as CEO, effective July 1, 2023. Dr. Hans Frickel, a trained pharmacist and industrial manager, brings more than 20 years of experience in strategic and operational leadership roles across the entire value chain of pharmaceuticals and medical devices. Prior to joining LEON, he served as Managing Director at R‑Biopharm and held several senior operational management roles at BioNTech, Evonik, Midas Pharma, Procter & Gamble and Merck. Dr. Hubert Birner, Chairman of the LEON Supervisory Board, said: “On behalf of the Supervisory Board, I am delighted to welcome Dr. Hans Frickel to LEON. With his extensive expertise in different areas of modern drug manufacturing, including plant management and QC, as well as a strong track record in strategy and governance, he is an ideal fit to take LEON to the next stage. On behalf of the Supervisory Board I also would like to thank our interim CEO and CFO Christian Nafe, our CSO Dr. Setu Kasera and their team for their tremendous work in driving our technology towards commercialization and for the great progress that has been achieved to date.” “I am excited to join LEON as we work to transform nanomedicine manufacturing,” said Dr. Hans Frickel, CEO of LEON. “I am impressed with the team’s knowledge and dedication in working to create added value across the nano formulation processing chain. I truly believe that LEON’s NANO devices will significantly improve development and manufacturing for current and future standardized and personalized cell & gene therapies at CDMOs, biotech and pharma companies.” ABOUT LEON-NANODRUGS leon-nanodrugs GmbH (“LEON”) is a pharmatech company specializing in the development and marketing of devices for the encapsulation of genetic material and other active substances into nanodrug carriers, such as lipid nanoparticles (LNPs). The Munich-based private company builds its innovative solutions based on its proprietary FR-JET Technology, enabling pharma companies and small biotechs as well as CDMOs to optimize nanomedicine manufacturing and take full advantage of the significant progress being made in advanced therapies. LEON's GMP-compliant, aseptic devices NANOme and NANOus increase efficiency in the production of nano drug carriers and are suitable for both clinical-scale and commercial production. In addition to its product offering, LEON will provide in-house lab capacity for process development with its own devices. For further information, please visit and follow us on LinkedIn and Twitter. CONTACT: MEDIA INQUIRIES: leon-nanodrugs GmbH Maja Tinko-Kuhar, Marketing Manager Phone: +49-89-41424889-98 e-mail: m.tinko-kuhar@leon-nanodrugs.com MC Services AG Katja Arnold / Eva Bauer Phone: +49-89-210228-0 e-mail: leon-nanodrugs@mc-services.eu Dr. Hans Frickel, CEO of leon-nanodrugs GmbH, © LEON For a high-res picture please contact leon-nanodrugs@mc-services.eu.

DUBLIN--( BUSINESS WIRE )--The "State of the Biopharmaceutical Industry 2023" report has been added to ResearchAndMarkets.com's offering. In this report, the publisher examines the business environment and trends that are going to shape the biopharmaceutical industry in 2023. The report highlights the most impactful emerging technologies, industry trends, regulatory trends, and microeconomic factors that are going to impact and dominate the industry throughout 2023. Synopsis The pharmaceutical industry is set to face new challenges such as inflation in a post-COVID-19 world. Genomics, RWE, and IO will dominate as the most impactful trends in the biopharmaceutical industry next year. Among the most impactful trends, genomics will be the key focus in 2023. Inflation and drug pricing pressures will be the top hindrances for pharmaceutical sector growth. Vertical integration, patent expiry of biologics, mega M&As, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry. Big data and AI will continue to dominate as transformational forces in the healthcare sector in 2023. Across the entire value chain, supply chains and manufacturing will be impacted the most by inflation in 2023. The biopharmaceutical industry is less optimistic about industry growth in the next 12 months compared to previous years. The pharmaceutical industry will continue to pursue its efforts to become more sustainable, with more companies committing to ESG strategies. Oncology, CNS, and infectious diseases will be the dominant areas for clinical trials initiated in 2023. Despite political rhetoric, COVID-19-induced pharmaceutical onshoring may not happen. While already met with skepticism by pharma, the Inflation Reduction Act will have to show if it can live up to its name. Key Highlights In 2023, economies and industries will continue to deal with inflationary pressures. Inflation will disrupt pharmaceutical manufacturing and supply chains. Genomics is the trend that will continue to have the greatest impact on the pharmaceutical industry in 2023. Inflation together with drug pricing and reimbursement-related concerns will be the leading impediment to industry growth. Vertical integration, patent expiry of biologics, mega M&As, and ESG factors will have the most positive impacts on industry. While less than in previous years, the biopharmaceutical industry is still optimistic about its growth in 2023. Scope Benchmark the impact of major themes on the biopharmaceutical industry in 2023, including: emerging technologies, regulatory trends, macroeconomic trends, industry trends. Identify themes that will have the greatest positive or negative impact in 2023. Capture opinions on these themes from industry respondents. Assess the impact of COVID-19 on the biopharmaceutical sector. Explore how inflation will affect the pharmaceutical industry in 2023. Reasons to Buy Stay up to date with the major emerging technologies, regulatory, macroeconomic, and industry trends that will impact the pharmaceutical industry in 2023. Explore how the biopharmaceutical landscape has changed. Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023. Gain insight into the regulatory and microeconomics trends that will have positive and negative effects on the biopharmaceutical industry. Identify emerging industry trends and innovations to gain a competitive advantage. A selection of companies mentioned in this report includes AbbVie Acceleron Pharma Atara Biotherapeutics Beta Pharma BioMarin Pharmaceutical BioNTech Bio-Thera Solutions Boehringer Ingelheim Bristol-Myers Squibb Catalent Celerity Pharmaceuticals Celltrion Coherus BioSciences CSL Behring CStone Pharmaceuticals CVS Health Corp EirGenix Eli Lilly Exelead Exscientia Ferring Pharmaceuticals Fuji Pharma GSK Immunocore Insud Pharma InventisBio Johnson & Johnson Johnson Matthey Legend Biotech Loxo Oncology Medicaid Health Plans of America Merck Merck & Co Metrics Contract Services Midas Pharma Mirati Therapeutics National Institute for Health and Care Excellence Nippon Kayaku Novartis Ono Pharmaceutical Optum Organon OS Therapies PTC Therapeutics Regeneron Pharmaceuticals Samsung Bioepis Sandoz Sarepta Therapeutics Shanghai Junshi Bioscience Sino Biopharmaceutical Stada Arzneimittel Stelis Biopharma Sumitomo Dainippon Pharma Oncology Teva Pharmaceutical Industries TRACON Pharmaceuticals UnitedHealth Group Veranova Xbrane Biopharma For more information about this report visit https://www.researchandmarkets.com/r/fix73o About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Pune, India, June 21, 2021 (GLOBE NEWSWIRE) -- Pharmaceutical Intermediates Market: Key InsightsAccording to our new research study on “Pharmaceutical Intermediates Market to 2028 – Global Analysis and Forecast – by Type, Application, Distribution Channel, and Geography,” the Pharmaceutical Intermediates Market Size is projected to reach US$ 37,290.33 million by 2028 from US$ 27,356.70 million in 2020; it is expected to grow at a CAGR of 4.2% during 2020–2028. Pharmaceutical Intermediates Market: Competition Landscape and Key DevelopmentsPfizer, Inc; Dishman Group; Dextra Laboratories Limited; Sanofi Winthrop Industries S.A; Vertellus Holdings LLC; BASF SE; Lianhetech; Codexis; Midas Pharma GmbH; and Chiracon GmbH are among the key companies operating in the pharmaceutical intermediates market. Leading players are focusing on the new product launch, expansion and diversification of their market presence, and acquisition of new customer base, thereby tapping prevailing business opportunities. In December 2019, Vertellus acquired Bercen Chemicals, a leading US-based supplier of alkyl succinic anhydrides and additives used in the fuel, lubricant, and paper industries. On the back of this acquisition, Vertellus is aiming to expand its offerings for the North American market, along with serving the global fuel and lubricant additives market more effectively. Get Exclusive Sample Pages of Pharmaceutical Intermediates Market - COVID-19 Impact and Global Analysis with Strategic Insights at In July 2019, BASF planned to invest in its second production plant for test-Butylamine (tBA) at BASF Specialty Chemicals Co. Ltd (BSNJ) in Nanjing, China. With this expansion, BASF’s global annual production capacity of tBA would increase by more than 30%. The plant is likely to resume operations in 2022 and would adopt advanced technologies of BASF to ensure the minimal generation of by-products in an advanced production process. BASF also operates tBA production plants in Antwerp, Belgium; and Geismar, Louisiana, US. In 2020, North America dominated the pharmaceutical intermediates market. The market growth in the region is credited to the factors such as increasing demand for pharmaceutical intermediates to produce APIs and growing support through initiatives to enhance pharmaceutical production, in addition to the factors driving the global market. Also, the growing pharmaceuticals industry in a Mexico is serving significant growth opportunities for the market players in the region. Based on type, the pharmaceutical intermediates market is segmented into GMP and non-GMP. The GMP segment held a larger share of the market in 2020 and is anticipated to register a higher CAGR in the market during the forecast period. The pharmaceutical intermediates market, by application, is segmented into antibiotics, antipyretic analgesics, vitamins, and others. The antibiotics segment held the largest share of the market in 2020, whereas the vitamins segment is anticipated to register the highest CAGR during the forecast period. Based on distribution channel, the pharmaceutical intermediates market is segmented as distributors and direct sales. The direct sales segment held a larger share of the market in 2020, while the distributor segment is estimated to register a higher CAGR during 2020–2028. Download Sample PDF Brochure of Pharmaceutical Intermediates Market Growth Research Report at Pharmaceutical Intermediates Market: Segmental OverviewBased on type, the GMP segment held a larger share of the pharmaceutical intermediates market in 2020. Good Manufacturing Practices (GMP) are regulations by the US Food and Drug Administration that ensure that pharmaceutical products are consistently produced as per the defined quality standards. These regulations are designed to reduce the risks involved in the production of pharmaceuticals. Under the GMP guidelines, all aspects of manufacturing— from the raw materials, premises, and equipment to the training and personal hygiene of the staff—are covered. Detailed written procedures are crucial for each process that might affect the quality of the final product. The growing developments are likely to develop such systems that would offer documented proof that correct procedures are constantly followed at every step in the manufacturing process - every time the product is produced. The market for the GMP segment is expected to grow at the fastest CAGR during the forecast period owing to continuously ongoing developments in GMP. Increasing Adoption of AI-based Tools for Drug Discovery to be Future Trend in Pharmaceutical Intermediates Market:Artificial intelligence (AI) is emerging as important tool as it helps understand the action mechanism of drugs. The use of AI tools has already been proven to accelerate the process of discovering new therapeutic candidates; the process that earlier used to take years for completion can now be accomplished within months using the AI. in addition to reducing the timelines of drug discovery, AI also helps enhance the agility of the research process, increase the accuracy of predictions regarding drug efficacy and safety, and boost the speed and precision of discovery as well as preclinical testing, thereby enabling more competitive R&D strategies. Direct Purchase Copy of Pharmaceutical Intermediates Market Research Study at Many of pharmaceutical players are collaborating with AI companies for drug discovery. For instance, In June 2017, Genentech collaborated with GNS Healthcare to use the proprietary REFS casual machine learning and simulation AI platform of the later to identify and validate novel cancer drug targets. Similarly, GlaxoSmithKline (GSK) collaborated with Insilico Medicine, a Baltimore-based AI-driven company, to explore the AI capability of Insilico for easing the process of identification of novel biological targets. Browse Related Reports:Pharmaceutical Solvent Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Chemical Group (Alcohol, Amine, Esters, Ethers, Chlorinated Solvents, Others) - Molecular Cytogenetics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Consumables, Software and Services, Instruments, Kits and Reagents); Technology (Comparative Genomic Hybridization, Fluorescence In Situ Hybridization (FISH), Immunohistochemistry, Karyotyping, Others); Application (Oncology, Personalized Medicine, Genetic Disorders, Others); End User (Hospitals, Clinical and Research Laboratories, Academic Research Institutes, Pharmaceutical and Biotechnology Companies) - About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer JoshiE-mail: sales@theinsightpartners.comPhone: +1-646-491-9876 Press Release -